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Abstract
Background There are two treatment strategies for
medication-resistant atrial fibrillation (AF): rhythm control
or rate control. It has been suggested that rate control is a
valid strategy in well-tolerated AF because it does not result in
increased mortality. We aimed to investigate the 1-year out-
come of rhythm control in an elderly population of AF
patients.
Method The study was retrospective, using the data collected
from electrocardioversions (ECV) of elderly patients and the
data of their follow-up visits to the outpatient clinic. We
looked for recurrence of AF within the first year after ECV.
Furthermore, we investigated possible predictors of
recurrence.
Results From February 2008 till November 2011, 436 con-
secutive elderly patients admitted for ECVwere included. The
1-year recurrence rate of AF was 51.3 %.We found that being
female and a large left atrial diameter were independent pre-
dictors of recurrence.
Conclusion The AF recurrence rate in our elderly population
is comparable with reported AF recurrence rates in a younger
population; we conclude that rhythm control can be regarded
as the viable strategy in persistent AF in elderly patients.
Keywords Atrial fibrillation . Elderly . ECV .
Electrocardioversion . Rate-control . Rhythm control
Background
Atrial fibrillation (AF) is the most common persistent arrhyth-
mia seen by physicians. The incidence of AF increases with
age. Population studies have shown a prevalence of AF of 8–
10.6 % in populations older than 75 years [1–3]. These num-
bers are increasing, because of prolonged life expectancy and
improved awareness of the condition of today’s mentally and
physically healthy elderly population. Two different treatment
options are used for persistent AF: rhythm or rate control. In
rhythm control, sinus rhythm is maintained or restored with
medication and serial electrocardioversion (ECV) or chemical
cardioversion. In rate control, particularly used in patients
with minor symptoms, AF is accepted and the heart rate, by
means of ventricular response, is controlled by medication[4].
However, the recurrence rate of AF after ECV in the elderly
population seems disappointingly high, [5,6] as compared
with the reported recurrence rate of 40–50%[7,8] in a younger
population. Patients in the rhythm-control treatment group
have a smaller chance of progressing to chronic AF[9,10].
Multicentre randomised clinical trials show no difference in
morbidity or mortality between asymptomatic patients treated
with either rhythm control or rate control[11,12]. The fact that
elderly patients have a higher chance of recurrence without a
difference in morbidity or mortality between the two strategies
suggests that the preferred treatment for the elderly is rate
control. However, elderly patients with minor symptoms due
to AF have indeed an increased risk of developing heart failure
and related admissions[13], which suggests that rhythm con-
trol would be the treatment of first choice in these patients.
However, current knowledge of predictors for successful
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rhythm control is limited. Neither echocardiographic nor clin-
ical parameters are powerful predictors[14,15].
Whether rhythm control is a valid treatment option for
daily clinical practice among elderly AF patients is not yet
determined. We therefore explored the 1-year outcome of all
consecutive elderly AF patients who underwent a successful
ECV in a large teaching hospital. Specifically, we explored the
determinants of AF recurrence, 1-year mortality, number of
strokes and major bleeding events.
Methods
This retrospective cohort study consisted of all consecutive
AF patients who were over 75 years of age and had a success-
ful ECV at Medical Centre Alkmaar between February 2008
and November 2011. All patients were treated according to
our ECV protocol, which included follow-up visits after 1 and
12 months. This allowed us to perform a 1-year follow-up of
all successful ECVs of patients older than 75 years. If patients
had another ECV after a recurrence, they were included as a
second ECV case. This happened in a few cases. Besides
regular visits, we used data from intermediate visits to the
emergency room or to other specialities. All data, including
patients demographic, clinical, and outcome characteristics,
were extracted from the clinical records.
The primary outcomes consisted of: AF recurrence within a
month, AF recurrence within 12 months. A recurrence of
persistent AF is defined as AF requiring intervention.
The secondary outcomes were: ischaemic events, major
bleeding events, all-cause mortality, adequacy of international
normalised ratio (INR) during ECV, type of rhythm medica-
tion for rate control and whether there was a switch to rate
control after recurrence. An ischaemic event was defined as
any stroke, transient ischaemic attack or pulmonary embo-
lism. A bleeding event was determined by fatal bleeding or
symptomatic bleeding in a critical area or organ, such as
intracranial, intraspinal, intraocular, retroperitoneal, intra-
articular or pericardial, or intramuscular with compartment
syndrome or needing transfusion. INR was considered inade-
quate if there was more than one measurement below 2 or
above 5 within 4 weeks prior to or 4 weeks after ECV.
For the first analysis two groups were used: patients
aged 75–79 years and patients aged >80 years. For the
second analysis two groups were made: a positive out-
come group (no recurrences within a year, no bleeding
events, no ischaemic events and no death) and a nega-
tive outcome group, i.e. chronic AF recurrence within a
year, bleeding events, ischaemic events or death. For the
third analysis two groups were used: patients who main-
tained rhythm control and patients who, after recurrence,
were switched to a rate-control strategy.
Statistics
To compare the characteristics of the different age groups, P-
values were calculated for all variables using the chi-square
test for categorical variables or independent samples t-test for
continuous variables. Overall statistical significance was set at
a two-tailed Pvalue <0.05. Cases were labelled as ECV not as
patients.
To compare age-related recurrence, log-rank test of the 75–
79 years and >80 years group were used to determine the
occurrence of the primary endpoint over time.
To determine predictors of a negative outcome, the groups
were compared for significant differences using univariate
analysis. The test variables were: gender, age, renal function,
left atrial diameter and history of heart failure, coronary dis-
ease, hypertension, diabetes and rhythm medication used at
the time of ECV.
We compared a rhythm-control group with a rate-control
group for significance using the appropriate tests already
mentioned above in comparison of age groups.
Results
A total of 477 consecutive successful ECVs were performed
in elderly patients fromwhich 41 cases were excluded because
of incomplete follow-up. The average age of the remaining
436 patients was 79.6 years and 46.6 % of them were female.
Slightly more than 70 % had hypertension and 65 % had a
normal left ventricular systolic function (Table 1). Their mean
CHA2DS2-VASc and HAS-BLED scores were 4.1 and 3.1
respectively. In the whole study there were 110 (25.3 %)
recurrences within a month and 224 (51.3 %) within a year.
Seven ischaemic events (1.7 %), 16 bleeding events (3.8 %)
and 22 deaths (5.4 %) occurred (Table 1).
Age-related outcome
ECV was performed in 229 (52.5 %) patients aged 75–79 and
in 207 (47.5 %) patients ≥80 years. Their mean ages were 76.9
and 82.7 years respectively with no patients >91 years, and
55.9 % and 50.7 % respectively were male. Univariate anal-
ysis showed no differences between the two groups with
respect to gender, cardiovascular risk factors, history of heart
failure, left ventricular function and renal function. Mortality
and recurrence rates of AF at 1 year were comparable between
the two groups (Fig. 1).
Predictors of ECV success in the elderly
There were 238 patients in the negative outcome group and
198 patients in the positive outcome group. The groups show
no significant differences in age, hypertension, mean
Neth Heart J (2014) 22:100–104 101
glomerular filtration rate (GFR) or percentage of patients with
a normal left ventricular ejection fraction. But there were more
females in the negative group (50.8 % vs. 41.4 %; p=0.05)
and more patients with a larger left atrial diameter in the
negative group (45.77 vs. 43.99; p=0.03). There were no
significant differences in use of antiarrhythmic medication.
Rhythm vs rate control
For this final analysis 36 more cases were excluded because
follow-up treatment after recurrence could not be determined.
The first group, the rhythm-control group, contained 236
cases and in the second group, the rate-control group, there
were 164 cases. The mean age of the patients in the first group
was 79.8 and in the second group 79.6. In the first group
44.5 % were female and in the second group 50.6 %. And
61 % of the patients in the first group had a normal left
ventricular function compared with 67.7 % of patients in the
second group. None of the characteristics mentioned differed
significantly between the two groups. The only baseline dif-
ference between the rhythm and rate-control group was
mean GFR (54.3 vs. 51.02; p=0.02). Baseline mean
creatinine was not different between the two groups
(105.5 vs. 110.9; p=0.23) (Table 2).
More bleeding events were seen in the rate-control group
(5.5 %) compared with the rhythm-control group (2.1 % p=
0.02). There was no significant difference in the number of
cases with an inappropriate INR (p=0.92) (Table 2).
Discussion
In this retrospective study data collected from ECVs of pa-
tients older than 75 years were used to assess the AF recur-
rence rate in the elderly patient. We tried to find predictors for
recurrence, events or death. And a comparison was made of
baseline characteristics between patients maintaining sinus
rhythm and patients who, after recurrence, were assigned to
rate control.
A 1-year recurrence rate of AF of circa 50 % was found.
This was not different for patients between 75 and 80 years of
age and patients older than 80 years. Nearly half of the
recurrences occurred within the first month. This result is
not different from the results of studies of the general
population[7,8]. This could mean that either the recurrence
in an elderly population is comparable with a younger popu-
lation or that this outcome could has been affected by selection
bias. There is a higher chance that the cardiologist chooses a
rhythm-control strategy for a healthier patient and vice-versa.
This is also evident in the Kaplan-Meier curve in which there
is no significant difference but a trend for older patients to
have a higher recurrence. This is also reported in the literature
[5,6].
Female gender and left atrial diameter were independent
predictors of negative outcome. These are known predictors
for negative outcome. Other predictors were not found; how-
ever, our study was relatively small. Future studies may give a
more decisive conclusion on predictors of AF recurrence after
ECV in the elderly.
Our 1-year analysis showed no significant differences in
mortality and ischaemic events in patients in rate control or in
rhythm control. This means that the conclusions of the RACE
trial[7], in which no difference in mortality was found in a
general population between a rate-control strategy and a
rhythm-control strategy, is also true for an elderly population.
Even though there was no difference in mortality, there were
significantly more bleeding events in the rate-control group.
There was no difference in inappropriate INR. This could
mean that elderly patients in rate control are either more prone
to bleeding events or that the significantly lower GFR was at
fault here.




Female (%) 203 (46.6)
Mean CHA2DS2-VASc 4.13
Mean HAS-BLED 3.1
Coronary disease (%) 134 (30.7)
Diabetic (%) 60 (13.8)
Hypertension (%) 320 (73.4)





Mean LA diameter 45.2
Normal EF (%) 278 (65.3)
Reduced EF (%) 105 (24.6)
Poor EF (%) 43 (9.9)
Outcome
Recurrences 1 month (%) 110 (25.3)
Recurrences 1 year (%) 224 (51.4)
Stroke 1 year (%) 7 (1.7)
Bleed 1 year (%) 16 (3.8)
Death 1 year (%) 22 (5.4)
Negative outcome (%) 238 (54.6)
Rate control (%) 161 (41.6)
Inappropriate INR (%) 91 (21.9)
EF ejection fraction; GFR glomerular filtration rate; INR international
normalised ratio; LA left atrial
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Even though there was no significant difference in mortal-
ity between patients in rhythm control and patients in rate
control, there could be a higher comorbidity burden in the
elderly. Left ventricular hypertrophy will be more common
and elderly patients will have worse renal function and more
frailty. The maintenance of atrioventricular synchrony is more
important in the elderly patient with less cardiac reserve and
more pronounced diastolic dysfunction. If they lose their atrial
kick, the diastolic filling is even less efficient resulting in heart
failure [16–18]. The difference in severity of perceived heart
failure symptoms and quality of life is difficult to determine in
a retrospective study. It would be interesting for future pro-
spective studies to compare quality of life for elderly patients
in either rate control or rhythm control.
Conclusion
From our study of ECVs in patients older than 75 years with
medication-resistant AF three conclusions can be drawn. First
of all, the recurrence rate of AF in elderly patients with
medication-resistant AF is comparable with younger patients.
Secondly, female gender and left atrial diameter were inde-
pendent predictors of negative outcome. These predictors
were also predictors of negative outcome in a population of
younger AF patients. Finally, there was no significant differ-
ence in mortality in elderly patients in either rhythm control or
in rate control. This would suggest that in the elderly a choice
between the two strategies should be made purely for reduc-
tion of symptoms and not for mortality reduction.
Table 2 Comparing baseline characteristics and outcome between pa-
tients with a rhythm-control strategy and patients on a rate-control strategy
Rhythm control Rate control p
n=236 n=164
Baseline characteristics
Mean age 79.8 79.6 0.54
Female (%) 105 (44.5) 83 (50.6) 0.23
Coronary disease (%) 79 (33.5) 48 (29.3) 0.07
Diabetic (%) 34 (14.4) 19 (11.6) 0.1
Hypertension (%) 173 (73.3) 122 (74.4) 0.63
History of heart failure (%) 48 (20.3) 36 (22) 0.44
Mean potassium 4.5 4.4 0.62
Mean creatinine 105.5 110.9 0.23
Mean GFR 54.3 51.02 0.02
Mean haemoglobin 8.8 8.5 0.58
Mean LA diameter 44.02 46.47 0.001
Normal EF (%) 144 (61) 111 (67.7) 0.22
Reduced EF (%) 61 (25.8) 35 (21.3) 0.27
Poor EF (%) 24 (10.2) 15 (9.1) 0.71
Outcome
Recurrences 1 month (%) 29 (12.3) 60(36.6) 0.001
Recurrences 1 year (%) 65 (27.5) 119 (72.6) 0.001
Stroke 1 year (%) 3 (1.3) 3 (1.8) 0.66
Bleed 1 year (%) 3 (1.3) 9 (5.5) 0.02
Death 1 year (%) 9 (3.8) 7 (4.3) 0.87
Inappropriate INR (%) 49 (20.8) 31 (18.9) 0.67
EF ejection fraction; GFR glomerular filtration rate; INR international
normalised ratio; LA left atrial
Fig. 1 Kaplan-Meier curve,
every event is a recurrence. Grey
line: Group 1: 75–79 years, black
line: group 2: ≥80 years. P=0.2,
timeline is in months
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